Price:
Rs. 9,595.00
Sample Type: EDTA BLOOD
EDTA BLOOD
Notes: I0300
Frequently Asked Questions (FAQ's):
What does this test include?
This test at Metropolis Healthcare analyzes the mutation status of the IGHV gene using EDTA blood to assess prognosis in CLL patients.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses advanced sequencing techniques to accurately detect IGHV gene mutations and classify disease subtype.
Who should take this test?
Patients diagnosed with Chronic Lymphocytic Leukemia or those requiring prognostic evaluation should consider testing at Metropolis Healthcare.
Why is this test important?
IGHV mutation status helps doctors understand disease behavior, treatment response, and long-term outlook based on reports provided by Metropolis Healthcare.
Do I need any preparation before sample collection at Metropolis Healthcare?
No special preparation is needed; a standard EDTA blood sample is collected for testing.
How long does it take to receive the results?
Metropolis Healthcare typically provides IGVH mutation analysis results within several working days, depending on sequencing requirements.
How are the results used for treatment decisions?
Results from Metropolis Healthcare help oncologists choose appropriate therapy options and predict potential treatment response.
Is this test safe?
Yes, the test is completely safe and involves a routine blood draw performed by trained professionals at Metropolis Healthcare